Biodexa Pharmaceuticals (BDRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.46, +5.82% vs the prior close of $0.43.
- Volume 608.35K shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BDRX jumps 5.8% to $0.46. Closed at $0.46, +5.82% vs the prior close of $0.43. Day range $0.44–$0.47, opened at $0.45.
BDRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BDRX jumps 5.8% to $0.46
- Closed at $0.46, +5.82% vs the prior close of $0.43. Day range $0.44–$0.47, opened at $0.45.
- Volume was 608.35K shares, 0.1x its 50-day average of 6.25M — lighter than usual.
- Price is -49.4% vs its 50-day average ($0.90) and -87.8% vs its 200-day average ($3.74).
- 52-week range $0.34–$44.70; today's close sits at 0% of that range, 99.0% below the 52-week high.
Oct 15, 2026 — BDRX slides 11.1% to $0.43
- Closed at $0.43, -11.13% vs the prior close of $0.49. Day range $0.41–$0.51, opened at $0.47.
- Volume was 1.65M shares, 0.3x its 50-day average of 6.20M — lighter than usual.
- Price is -53.3% vs its 50-day average ($0.92) and -88.6% vs its 200-day average ($3.79).
- 52-week range $0.34–$44.70; today's close sits at 0% of that range, 99.0% below the 52-week high.
Oct 14, 2026 — BDRX jumps 38.6% to $0.49 on 10.3x normal volume
- Closed at $0.49, +38.57% vs the prior close of $0.35. Day range $0.40–$0.54, opened at $0.50.
- Volume was 53.24M shares, 10.3x its 50-day average of 5.15M — unusually heavy trading.
- Price is -48.7% vs its 50-day average ($0.95) and -87.4% vs its 200-day average ($3.85).
- 52-week range $0.34–$44.70; today's close sits at 0% of that range, 98.9% below the 52-week high.
- SEC filings that day: 6-K.
Oct 13, 2026 — BDRX slides 8.6% to $0.35, a 52-week low on 4.9x normal volume
- Closed at $0.35, -8.62% vs the prior close of $0.38. Day range $0.34–$0.42, opened at $0.42.
- Volume was 22.98M shares, 4.9x its 50-day average of 4.69M — unusually heavy trading.
- Price is -63.7% vs its 50-day average ($0.97) and -91.0% vs its 200-day average ($3.91).
- 52-week range $0.34–$44.80; today's close sits at 0% of that range, 99.2% below the 52-week high.
- That makes 9 straight losses.
Oct 12, 2026 — BDRX slides 16.7% to $0.38, a 52-week low, 8 down days in a row
- Closed at $0.38, -16.74% vs the prior close of $0.46. Day range $0.38–$0.47, opened at $0.47.
- Volume was 265.60K shares, 0.1x its 50-day average of 4.68M — lighter than usual.
- Price is -61.2% vs its 50-day average ($0.99) and -90.4% vs its 200-day average ($3.98).
- 52-week range $0.38–$52.05; today's close sits at 0% of that range, 99.3% below the 52-week high.
- That makes 8 straight losses.
Oct 9, 2026 — BDRX slides 12.2% to $0.46, a 52-week low, 7 down days in a row
- Closed at $0.46, -12.21% vs the prior close of $0.52. Day range $0.45–$0.52, opened at $0.52.
- Volume was 156.80K shares, 0.0x its 50-day average of 4.68M — lighter than usual.
- Price is -54.3% vs its 50-day average ($1.01) and -88.7% vs its 200-day average ($4.06).
- 52-week range $0.45–$59.40; today's close sits at 0% of that range, 99.2% below the 52-week high.
- That makes 7 straight losses.
Oct 8, 2026 — BDRX slides 7.1% to $0.52, a 52-week low, 6 down days in a row
- Closed at $0.52, -7.09% vs the prior close of $0.56. Day range $0.51–$0.55, opened at $0.55.
- Volume was 105.90K shares, 0.0x its 50-day average of 4.68M — lighter than usual.
- Price is -48.9% vs its 50-day average ($1.03) and -87.3% vs its 200-day average ($4.14).
- 52-week range $0.51–$59.40; today's close sits at 0% of that range, 99.1% below the 52-week high.
- That makes 6 straight losses.
- SEC filings that day: 6-K.
Oct 7, 2026 — BDRX slides 5.2% to $0.56, a 52-week low, 5 down days in a row
- Closed at $0.56, -5.21% vs the prior close of $0.60. Day range $0.53–$0.59, opened at $0.57.
- Volume was 149.30K shares, 0.0x its 50-day average of 4.68M — lighter than usual.
- Price is -46.0% vs its 50-day average ($1.04) and -86.7% vs its 200-day average ($4.23).
- 52-week range $0.53–$59.40; today's close sits at 0% of that range, 99.1% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — BDRX slides 3.1% to $0.60, a 52-week low, 4 down days in a row
- Closed at $0.60, -3.09% vs the prior close of $0.61. Day range $0.59–$0.64, opened at $0.62.
- Volume was 273.80K shares, 0.1x its 50-day average of 4.67M — lighter than usual.
- Price is -44.0% vs its 50-day average ($1.06) and -86.3% vs its 200-day average ($4.33).
- 52-week range $0.57–$59.40; today's close sits at 0% of that range, 99.0% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — BDRX dips 1.0% to $0.61, a 52-week low, 3 down days in a row
- Closed at $0.61, -0.97% vs the prior close of $0.62. Day range $0.60–$0.62, opened at $0.62.
- Volume was 103.20K shares, 0.0x its 50-day average of 4.67M — lighter than usual.
- Price is -43.2% vs its 50-day average ($1.08) and -86.2% vs its 200-day average ($4.46).
- 52-week range $0.57–$59.40; today's close sits at 0% of that range, 99.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — BDRX dips 2.1% to $0.62, a 52-week low
- Closed at $0.62, -2.05% vs the prior close of $0.63. Day range $0.57–$0.63, opened at $0.63.
- Volume was 185.80K shares, 0.0x its 50-day average of 4.67M — lighter than usual.
- Price is -43.7% vs its 50-day average ($1.10) and -86.6% vs its 200-day average ($4.62).
- 52-week range $0.57–$59.40; today's close sits at 0% of that range, 99.0% below the 52-week high.
BDRX latest news & SEC filings
Every SEC filing by or about BDRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 6, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 30, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 24, 2026 · Form F-1 — F-1 filing
F-1 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 15, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 15, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade BDRX
- How much it moves: over the last 20 sessions the average daily move was 6.64% (largest 38.6%). That is a volatile stock.
- Liquidity: about 4.19M shares (≈$1.91M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.46 vs a range of $0.34–$44.70 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:5 on Apr 6, 2026, 1:10 on Jul 31, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Oct 14, 2026; 6-K Oct 8, 2026; 6-K Sep 15, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BDRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.45 | 0.47 | 0.44 | 0.46 | 608.35K |
| Oct 15, 2026 | 0.47 | 0.51 | 0.41 | 0.43 | 2.99M |
| Oct 14, 2026 | 0.50 | 0.54 | 0.40 | 0.49 | 53.24M |
| Oct 13, 2026 | 0.42 | 0.42 | 0.34 | 0.35 | 22.98M |
| Oct 12, 2026 | 0.47 | 0.47 | 0.38 | 0.38 | 265.60K |
| Oct 9, 2026 | 0.52 | 0.52 | 0.45 | 0.46 | 156.80K |
| Oct 8, 2026 | 0.55 | 0.55 | 0.51 | 0.52 | 105.90K |
| Oct 7, 2026 | 0.57 | 0.59 | 0.53 | 0.56 | 149.30K |
| Oct 6, 2026 | 0.62 | 0.64 | 0.59 | 0.60 | 273.80K |
| Oct 5, 2026 | 0.62 | 0.62 | 0.60 | 0.61 | 103.20K |
| Oct 2, 2026 | 0.63 | 0.63 | 0.57 | 0.62 | 185.80K |
| Oct 1, 2026 | 0.67 | 0.67 | 0.60 | 0.63 | 251.90K |
| Sep 30, 2026 | 0.65 | 0.66 | 0.63 | 0.66 | 147.50K |
| Sep 29, 2026 | 0.68 | 0.68 | 0.64 | 0.64 | 142.60K |
| Sep 28, 2026 | 0.67 | 0.68 | 0.64 | 0.68 | 162.70K |
| Sep 25, 2026 | 0.66 | 0.69 | 0.65 | 0.68 | 163.40K |
| Sep 24, 2026 | 0.67 | 0.69 | 0.66 | 0.68 | 126.60K |
| Sep 23, 2026 | 0.68 | 0.73 | 0.65 | 0.69 | 365.30K |
| Sep 22, 2026 | 0.67 | 0.69 | 0.61 | 0.68 | 745.60K |
| Sep 21, 2026 | 0.74 | 0.74 | 0.62 | 0.68 | 622.50K |
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals (BDRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CARDIFF. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1643918.
BDRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ann Louise Merchant | Director | Mar 18, 2026 |
| Stephen Barry Parker | Director | Mar 20, 2026 |
| Fiona Mary Powell | Chief Financial Officer | Mar 18, 2026 |
| Stephen Anthony Stamp | Chief Executive Officer | Mar 18, 2026 |
| Simon Turton | Director | Mar 18, 2026 |
| Vries Simon De | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Fiona Mary Powell | Chief Financial Officer | Mar 18, 2026 |
| Stephen Anthony Stamp | Chief Executive Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
BDRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
BDRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BDRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.